Medication info
Nexiome Tablets 20 mg (Esomeprazole Magnesium Trihydrate)

Nexiome Tablets 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
Light pink, oblong film-coated tablet
Packaging
28 tablets/box [7 tablets/Alu-Alu×4]
Approval status
Active

MFDS item code 201605615 · Approved 2016.09.22 · Insurance code 647303200

Summary

Main use
Treatment and prevention of gastric acid-related diseases (such as reflux disease), Helicobacter pylori eradication, and gastrointestinal symptoms and ulcers
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms can be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed treatment to control recurrent symptoms is not recommended in patients at high risk of developing gastric or duodenal ulcers due to NSAID use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous NSAID treatment - Treatment of gastric ulcers associated with NSAID use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with NSAID use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this drug to patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this drug should not exceed 20 mg in patients with severe hepatic impairment. 6. Older adults: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms can be controlled with 20 mg once daily. 3. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment and prevention of gastric acid-related diseases (such as reflux disease), Helicobacter pylori eradication, and gastrointestinal symptoms and ulcers

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, particularly erosive reflux esophagitis and maintenance therapy to prevent the recurrence of esophagitis. It also helps in the treatment and prevention of recurrence of duodenal and peptic ulcers caused by Helicobacter pylori infection. It is effective for the short-term treatment of gastrointestinal symptoms associated with the use of non-steroidal anti-inflammatory drugs and for the treatment and prevention of gastric ulcers due to continuous pain medication use. Additionally, it is used in the treatment of Zollinger-Ellison syndrome and maintenance therapy to prevent rebleeding from gastric or duodenal ulcers, improving the patients' symptoms.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms can be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed treatment to control recurrent symptoms is not recommended in patients at high risk of developing gastric or duodenal ulcers due to NSAID use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous NSAID treatment - Treatment of gastric ulcers associated with NSAID use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with NSAID use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this drug to patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this drug should not exceed 20 mg in patients with severe hepatic impairment. 6. Older adults: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms can be controlled with 20 mg once daily. 3. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be used in patients who have had allergic reactions or hypersensitivity to any of its components. Additionally, it should not be used in patients currently taking specific antibiotics or other drugs, breastfeeding mothers, or patients with a history of heart disease. This medication contains Yellow No. 5, and patients with an allergic reaction to this ingredient should exercise caution. Rarely, various side effects such as hematological abnormalities, allergic reactions, electrolyte imbalance, neurological disorders, gastrointestinal disturbances, liver function abnormalities, skin rashes, etc., may occur, so immediate consultation with a doctor is advised if symptoms arise. Regular blood tests and electrolyte levels should be checked during long-term use. This medication may interact with other drugs, so if the patient is taking other medications, they must inform their doctor or pharmacist. Caution is especially required when used in conjunction with certain antibiotics, antiviral drugs, anti-coagulants, etc. Pregnant or breastfeeding women should consult with healthcare providers before using this medication. In case of overdose, there is no specific antidote, so symptomatic treatment is crucial. This medication should be kept out of reach of children, and transferring it to another container may change its quality, so caution is advised.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, agitation, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbances, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field loss, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, angioedema, otitis media, olfactory disturbances, loss of taste, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric pseudopolyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Light pink, oblong film-coated tablet

Package unit

28 tablets/box [7 tablets/Alu-Alu×4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.